MedTrace Logo

Barricaid EU Post Market Study for Primary Lumbar Disc Herniation

NCT01534065 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-04-08

No results posted yet for this study

Summary

The purpose of this multi-center post marketing surveillance study is to monitor the safety and performance of the Barricaid® ARD when used to surgically reconstruct the anulus of the L1 - S1 spinal disc.

Conditions

  • Lumbar Disc Herniation

Interventions

DEVICE

Barricaid

Implanted intra-operatively during discectomy

Sponsors & Collaborators

  • Intrinsic Therapeutics

    lead INDUSTRY

Principal Investigators

  • Claudius Thome, PhD · University of Innsbruck, Department of Neurosurgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01534065 on ClinicalTrials.gov